...
首页> 外文期刊>Oncology research and treatment. >Is a Surgical Approach Justified in Metachronous Krukenberg Tumor from Gastric Cancer? A Systematic Review
【24h】

Is a Surgical Approach Justified in Metachronous Krukenberg Tumor from Gastric Cancer? A Systematic Review

机译:是一种外科手术方法,在胃癌中的krukenberg肿瘤中有合理吗? 系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The treatment of metachronous Krukenberg tumor (mKT) from gastric cancer remains unexplored. We performed a literature review to evaluate whether or not surgical treatment improves survival. Methods: A systematic review according to PRISMA guidelines was performed. Studies reporting on patients who underwent surgical treatment for mKT from gastric cancer were selected. Metachronous disease was divided as follows: confined to the ovaries, confined to the pelvis, or beyond the pelvis. Outcomes evaluated included overall survival (OS), progression-free survival (PFS), resection rate (R0), and factors predicting survival. Results: 13 retrospective reports fulfilled the selection criteria (512 patients). Most of the patients presented at a premenopausal age. The median presentation interval from gastrectomy ranged from 16 to 21.4 months. Median OS ranged between 9 and 36 months. 1-year OS ranged between 52.5 and 59%, and 3-years OS between 9.8 and 36.5%. Resection margin, peritoneal seeding, and chemotherapy regimen and cycles influenced survival. Conclusion: Surgical treatment and adjuvant chemotherapy in patients with mKT from gastric cancer seems to be associated with improved survival and is justified especially in young patients. Disease location and R0 resection should be considered when selecting patients. (C) 2018 S. Karger GmbH, Freiburg.
机译:背景:来自胃癌的同勤Krukenberg肿瘤(MKT)的治疗仍未开发。我们进行了文献综述以评估手术治疗是否改善生存。方法:根据PRISMA指南进行系统审查。选择了研究胃癌MKT手术治疗的患者的研究报告。比较疾病如下:限制在卵巢上,限制在骨盆之外,或超越骨盆。评估的结果包括整体存活(OS),无进展存活(PFS),切除率(R0)和预测存活的因素。结果:13回顾性报告满足了选择标准(512名患者)。大多数患者在前一年级呈现。来自胃切除术的中位呈现间隔范围为16至21.4个月。中位数操作系统在9到36个月之间。 1年的OS范围在52.5和59%之间,3年oS在9.8%和36.5%之间。切除边缘,腹膜播种和化疗方案和循环影响生存。结论:胃癌中MKT患者的外科治疗和辅助化疗似乎与改善的存活有关,特别是在年轻患者中有理由。选择患者时,应考虑疾病位置和R0切除术。 (c)2018年S. Karger GmbH,Freiburg。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号